Compare AMRN & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRN | ARMP |
|---|---|---|
| Founded | 1989 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.1M | 295.5M |
| IPO Year | 1998 | 1996 |
| Metric | AMRN | ARMP |
|---|---|---|
| Price | $16.01 | $7.09 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 78.9K | 54.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.22 | N/A |
| 52 Week Low | $12.96 | $1.81 |
| 52 Week High | $20.90 | $14.98 |
| Indicator | AMRN | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 38.34 |
| Support Level | $13.58 | $4.96 |
| Resistance Level | $17.00 | $7.70 |
| Average True Range (ATR) | 0.66 | 0.65 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 89.83 | 36.04 |
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.